More intelligence articles

Nudge-nudge, think-think

Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes

Quality in Care Diabetes 2018: the best in innovative diabetes care

Awards highlight new evidence-based approaches to improving care

The handover: Pfizer reshapes itself for a new era

There is a new leader at the world's biggest pharma company - but just how much is set to change at Pfizer?

Brexit: can pharma 'take back control' of the narrative?

Four Public Affairs managing director Sarah Jones talks to PME about the risks of Brexit - and how the sector musn't let the long-term issues become obscured

In conversation with Pfizer’s Erik Nordkamp

Pfizer’s UK managing director and newly appointed ABPI President talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

Retaining reader value in plain language summaries of clinical studies

Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries

Making Europe a leader in bioscience: boosting trust and opening minds

A vision of Paris as Europe's leading hub for life sciences innovation

Tackling a formidable foe

Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

Redefining communications excellence

How to be heard in today’s multichannel, multistakeholder, multimedia world

AstraZeneca: building a new ‘open innovation’ pharma company

The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects

Pharma social media

Posting frequency is down as companies take a ‘less is more’ approach

The case for a second Brexit referendum: “We need the informed consent of the people”

Dr Phillip Lee MP is fighting to keep the UK in the EMA network - and for a second referendum